Evidence map›Paper›PMID 37005953›Full record

ArticleHepatology international2023

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.

Mathew Vithayathil, Antonio D'Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida, Martin Schönlein, Johann von Felden, Kornelius Schulze, Henning Wege, Anwaar Saeed, Brooke Wietharn and 25 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

35 authors at 16 institutions in 7 countries.

Mathew VithayathilDepartment of Surgery & Cancer, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0HS, UK.
Antonio D'AlessioDepartment of Surgery & Cancer, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0HS, UK.
Claudia Angela Maria FulgenziDepartment of Surgery & Cancer, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0HS, UK.
Naoshi NishidaDepartment of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University, Osaka, Japan.
Martin SchönleinDepartment of Oncology, Hematology and Bone Marrow Transplantation With Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Johann von FeldenDepartment of Gastroenterology and Hepatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Kornelius SchulzeDepartment of Gastroenterology and Hepatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Henning WegeDepartment of Gastroenterology and Hepatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Anwaar SaeedDivision of Medical Oncology, Department of Medicine, Kansas University Cancer Center, Kansas City, KS, USA.
Brooke WietharnDivision of Medical Oncology, Department of Medicine, Kansas University Cancer Center, Kansas City, KS, USA.
Hannah HildebrandDivision of Medical Oncology, Department of Medicine, Kansas University Cancer Center, Kansas City, KS, USA.
Linda WuDivision of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Mount Sinai Hospital, New York, NY, USA.
Celina AngDivision of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Mount Sinai Hospital, New York, NY, USA.
Thomas U MarronDivision of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Mount Sinai Hospital, New York, NY, USA.
Arndt WeinmannI. Medical Department, University Medical Center Mainz, Mainz, Germany.
Peter R GalleI. Medical Department, University Medical Center Mainz, Mainz, Germany.
Dominik BettingerDepartment of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Faculty of Medicine, Freiburg University Medical Center, University of Freiburg, Freiburg, Germany.
Bertram BengschDepartment of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Faculty of Medicine, Freiburg University Medical Center, University of Freiburg, Freiburg, Germany.
Arndt VogelHannover Medical School, Hannover, Germany.
Lorenz BalcarDivision of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Bernhard ScheinerDivision of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Pei-Chang LeeDivision of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Yi-Hsiang HuangDivision of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Suneetha AmaraDivision of Hematology/Oncology, East Carolina University, Greenville, NC, USA.
Mahvish MuzaffarDivision of Hematology/Oncology, East Carolina University, Greenville, NC, USA.
Abdul Rafeh NaqashDivision of Hematology/Oncology, East Carolina University, Greenville, NC, USA.
Antonella CammarotaDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Valentina ZanusoDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Tiziana PressianiMedical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Matthias PinterDivision of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Alessio CortelliniDepartment of Surgery & Cancer, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0HS, UK.
Masatoshi KudoDepartment of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University, Osaka, Japan.
Lorenza RimassaDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
David J PinatoDepartment of Surgery & Cancer, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0HS, UK.
Rohini SharmaDepartment of Surgery & Cancer, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0HS, UK. r.sharma@imperial.ac.uk.
Imperial College London · GBIRCCS Humanitas Research Hospital · ITUniversität Hamburg · DEMedical University of Vienna · ATMount Sinai Hospital · USThe University of Kansas Cancer Center · USEast Carolina University · USKindai University · JPUniversity Medical Center Freiburg · DEUniversity Medical Center of the Johannes Gutenberg University Mainz · DEHumanitas University · ITMedizinische Hochschule Hannover · DENational Yang Ming Chiao Tung University · TWTaipei Veterans General Hospital · TWUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity of Oklahoma · US

Funding

Wellcome TrustWellcome Trust PS3416
6 · The paper itself

Abstract

backgroundAtezolizumab plus bevacizumab (Atezo/Bev) is first line-treatment for unresectable hepatocellular carcinoma (HCC). Body mass index (BMI) has demonstrated predictive value for response to immunotherapy in non-HCC cancer types. Our study investigated the effect of BMI on safety and efficacy of real-life use of Atezo/Bev for unresectable HCC.

methods191 consecutive patients from seven centres receiving Atezo/Bev were included in the retrospective study. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR) defined by RECIST v1.1 were measured in overweight (BMI ≥ 25) and non-overweight (BMI < 25) patients. Treatment-related adverse events (trAEs) were evaluated.

resultsPatients in the overweight cohort (n = 94) had higher rates of non-alcoholic fatty liver disease (NAFLD) and lower rates of Hepatitis B compared to non-overweight cohort (n = 97). Baseline Child-Pugh class and Barcelona Clinic Liver Cancer stage were similar between cohorts, with lower rates of extrahepatic spread in the overweight group. Overweight patients had similar OS compared to non-overweight (median OS 15.1 vs. 14.9 months; p = 0.99). BMI did not influence median PFS (7.1 vs. 6.1 months; p = 0.42), ORR (27.2% vs. 22.0%; p = 0.44) and DCR (74.1% vs. 71.9%; p = 0.46). There were higher rates of atezolizumab-related fatigue (22.3% vs. 10.3%; p = 0.02) and bevacizumab-related thrombosis (8.5% vs. 2.1%; p = 0.045) in the overweight patients, but overall trAEs and treatment discontinuation were comparable between cohorts.

conclusionAtezo/Bev has comparable efficacy in overweight HCC patients, with an increase in treatment-related fatigue and thrombosis. Combination therapy is safe and efficacious to use in overweight patients, including those with underlying NAFLD.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsNon-alcoholic Fatty Liver DiseaseAntibodies, Monoclonal, HumanizedBevacizumabBody Mass IndexFatigueHumansRetrospective StudiesUbiquitin-Protein LigasesAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabUbiquitin-Protein LigasesAnti-programmed death-ligandAnti-vascular endothelial growth factorCheckpoint inhibitorCirrhosisImmunotherapyNon-alcoholic fatty liver diseaseObesityOverall survivalOverweightProgression-free survival

Identifiers

PMID37005953
PMCPMC10386929
OpenAlexW4362505786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.